Aripiprazole monotherapy in acute mania: 12-Week randomised placebo- and haloperidol-controlled study

British Journal of Psychiatry

Volumn 194, Issue 1, 2009, Pages 40-48

  Young, Allan H ^a   Oren, Dan A ^b   Lowy, Adam ^c   McQuade, Robert D ^d   Marcus, Ronald N ^b   Carson, William H ^d   Spiller, Nina H ^b   Torbeyns, Anne F ^b   Sanchez, Raymond ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRISTOL MYERS SQUIBB   (United States)

^c Univ S Carolina Sch Med Vice P   (United States)

^d OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIPYRETIC AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; BENZATROPINE; BENZODIAZEPINE DERIVATIVE; BIPERIDEN; HALOPERIDOL; PLACEBO; PROPRANOLOL; TRIHEXYPHENIDYL;

ADULT; AKATHISIA; ARTICLE; BIPOLAR I DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; HUMAN; INSOMNIA; MAINTENANCE THERAPY; MANIA; MENTAL DISEASE; MUSCLE RIGIDITY; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREMOR; YOUNG MANIA RATING SCALE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; QUINOLONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 58149398256     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.108.049965     Document Type: Article

References (31)

1. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381-9.
2. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28: 1400-11.
3. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol 2002; 441: 137-40.
4. Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 2004; 18: 375-83.
5. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004; 483: 45-53.
6. Keck PE, Jr., Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160: 1651-8.
7. Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006; 20: 536-46.
8. Keck PE, Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 67: 626-37.
9. Keck PE, Jr, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007; 68: 1480-91.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM-IV-TR). APA, 2000.
11. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-35.
12. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9.
13. Spearing MK, Port RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997; 73: 159-71.
14. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76.
15. White L, Harvey PD, Opler L, Lindenmayer JP. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. Psychopathology 1997; 30: 263-74.
16. Leon AC, Solomon DA, Mueller TI, Endicott J, Posternak M, Judd LL, et al. A brief assessment of psychosocial functioning of subjects with bipolar I disorder: the LIFE-RIFT. Longitudinal Interval Follow-up Evaluation-Range Impaired Functioning Tool. J Nerv Ment Disord 2000; 188: 805-12.
17. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-9.
18. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-6.
19. Guy W. Abnormal Involuntary Movement Scale (AIMS). In ECDEU Assessment Manual for Psychopharmacology: 534-7. US Department of Health, Education and Welfare, 1976.
20. Sachs G, Gaulin B, Gutierrez-Esteinou R, McQuade R, Pikalov A, Pultz J, et al. Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline. J Clin Psychiatry 2007; 68: 1377-83.
21. Vieta E, Bourin M, Sanchez R, Marcus R, Stock E, McQuade R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania. Double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005; 187: 235-42.
22. Keck PE, Orsulak PJ, Cutler AJ, Sanchez R, Torbeyns A, Marcus RN, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord 2008; Oct 2: Epub ahead of print.
23. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003; 60: 1218-26.
24. Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005; 66: 111-21.
25. McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J. Quetiapine or haloperidol as monotherapy for bipolar mania - a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005; 15: 573-85.
26. Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 2005; 15: 75-84.
27. Vieta E, Carne X. The use of placebo in clinical trials on bipolar disorder: a new approach for an old debate. Psychother Psychosom 2005; 74: 10-6.
28. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000; 57: 841-9.
29. Nasrallah HA, Churchill CM, Hamdan-Allan GA. Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia. Am J Psychiatry 1988; 145: 1455-6.
30. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982; 39: 473-81.
31. McIntyre RS, Konarski JZ, Soczynska JK, Wilkins K, Panjwani G, Bouffard B, et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv 2006; 57: 1140-4.